Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by general360on Apr 27, 2021 3:46pm
228 Views
Post# 33076146

RE:CALGARY, Alberta, April 27, 2021 (GLOBE NEWSWIRE)

RE:CALGARY, Alberta, April 27, 2021 (GLOBE NEWSWIRE)
oh goody, another publication!  are we red on the day yet!?!?

havent we been waiting for like over a year now on this pub?  the kidney results from Bom1?  going to take my time reading this one, looks really good.  no beef w/ the science, thats for sure...unfortunately, as i see more and more publications coming out, in the #2 journal (Cell) or other top-tier journals, it just makes me madder and madder as i look at our share price and scratch my head and wonder WTF is going on as true value diverges significantly from perceived value...

1 more week to go and we hit 3 freakin months for our "immediately filing" for our P2 for COVID, er, SARS-COVID, er, SARS-Cov2, whatever.  3 months to wait, for our "immediate filing", predominatly in the US.... of course, after that 2.5mo waiting, we've also heard (we're 15 days past when) we were told "Authorization to Begin Immediate Clinical Studies"....in canada....wait, in the US, no, in Canada... so we're cleared pretty much everywhere in north america yet here we sit.... is the FDA the holdup in setting up a trial in the US? with our fastrack BTD we can't get them to approve a trial design?  is that the hold up here?

why'd we even bother to go after IMMEDIATE authorization from Health Canada if we're gonna sit on it and do NUTHIN.....all that filing and we didnt have a plan?

we do have a plan, dont we?  im sorry, but we're at least 6 or 7 months past the "by the end of the year", and now 3 months past "immediate" filing... can you update us, or stop using language that makes it sound like you don't know the english language....

IMMEDIATE=NOW.  your words, not mine! at least immediate means the same in Canada as in the US; JACK-SHYTE!!!


unbelievable.....
<< Previous
Bullboard Posts
Next >>